developing therapeutic antibodies targeting Siglec receptors
Lead Programs Focused on Inhibiting Mast Cell and/or Eosinophil Activation
mast cells and eosinophils are pathogenic in a number of inflammatory diseases
an investigational monoclonal antibody that depletes eosinophils and inhibits mast cells
an investigational monoclonal antibody that selectively and potently inhibits mast cells, including KIT mediated signaling